Receptor News and Research

RSS

Encouraging results from Tonix TNX-102 SL clinical trial for fibromyalgia syndrome

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system, including fibromyalgia syndrome and post-traumatic stress disorder, announces that the clinical portion of a human study of a solution version of TNX-102 2.4 mg sublingual tablets has completed.

30 Jul 2012

Study extends scientific understanding of how pheromones activate the vomeronasal organ

The vomeronasal organ (VNO) is one of evolution's most direct enforcers. From its niche within the nose in most land-based vertebrates, it detects pheromones and triggers corresponding basic-instinct behaviors, from compulsive mating to male-on-male death matches. A new study from the Stowers Institute for Medical Research, published online in Nature Neuroscience on July 29, 2012, extends the scientific understanding of how pheromones activate the VNO, and has implications for sensory transduction experiments in other fields.

30 Jul 2012

Fruit flies help pinpoint genetic changes that spell cancer

By studying fruit flies, scientists at A*STAR's Institute of Molecular and Cell Biology (IMCB) have successfully devised a fast and cost-saving way to uncover genetic changes that have a higher potential to cause cancer. With this new approach, researchers will now be able to rapidly distinguish the range of genetic changes that are causally linked to cancer (i.e. "driver" mutations) versus those with limited impact on cancer progression.

30 Jul 2012

New drug can aid in losing weight and keeping it off

A new drug could aid in losing weight and keeping it off. The drug, described in the journal Cell Metabolism on July 26, increases sensitivity to the hormone leptin, a natural appetite suppressant found in the body. Although so far the new drug has only been tested on mice, the findings have implications for the development of new treatments for obesity in humans.

28 Jul 2012

A2bAR receptor plays a significant role in regulation of type 2 diabetes and obesity

A recent study led by Boston University School of Medicine (BUSM) demonstrates that the A2b-type adenosine receptor, A2bAR, plays a significant role in the regulation of high fat, high cholesterol diet-induced symptoms of type 2 diabetes.

27 Jul 2012

Navidea announces results from Lymphoseek Phase 3 trial on head and neck squamous cell carcinoma

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, noted today that individual site, investigator-initiated results of an ongoing Phase 3 clinical trial of 99m-Tc-Tilmanocept (Lymphoseek) were presented at the American Head and Neck Society's 8th International Conference on Head and Neck Cancer (ICHNC), held in Toronto, July 21-25, 2012.

27 Jul 2012

Fusion of FGFR and TACC gene leads to glioblastoma

Researchers at Columbia University Medical Center (CUMC) have discovered that some cases of glioblastoma, the most common and aggressive form of primary brain cancer, are caused by the fusion of two adjacent genes.

26 Jul 2012

Insomnia: an interview with Dr Darryle Schoepp

Insomnia is a very common disorder. In medical terms it can affect a third of people. It affects elderly as well as non-elderly people, and is more common in women.

26 Jul 2012

Molecular explanation for increased susceptibility to intestinal inflammation in malnutrition

More than one billion people in poor countries are starving, and malnutrition remains a major problem even in rich countries, making it a leading cause of death in the world. For over a hundred years, doctors have known that a lack of protein in the diet or low levels of amino acids, the building blocks of proteins, can lead to symptoms like diarrhoea, inflamed intestines and other immune system disorders, which weaken the body and can be fatal. However, the molecular mechanism which explains how malnutrition causes such severe symptoms has been largely unexplored.

26 Jul 2012

MASL protein from plant's seeds may halt spread of melanoma

An international team of scientists led by Gary Goldberg, PhD, of the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine (UMDNJ-SOM), has found that a protein from the seeds of a plant used for centuries in traditional medicines may be able to halt the spread of melanoma, a lethal form of skin cancer.

25 Jul 2012

Mice have different neural subsystem associated with instinctually important smells

A new study finds that mice have a distinct neural subsystem that links the nose to the brain and is associated with instinctually important smells such as those emitted by predators. That insight, published online this week in Proceedings of the National Academy of Sciences, prompts the question whether mice and other mammals have specially hardwired neural circuitry to trigger instinctive behavior in response to certain smells.

25 Jul 2012

Biokine receives FDA Orphan Drug designation for BKT140 to treat hematological cancers

Biokine Therapeutics Ltd. announced today that it has received Orphan Drug designation from the US Food and Drug Administration (FDA) for the mobilization of hematopoietic stem cells from bone marrow into peripheral blood for collection and subsequent transplantation in patients with hematological cancers.

24 Jul 2012

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

Adding motesanib to carboplatin–paclitaxel does not boost overall survival in patients with advanced nonsquamous non-small-cell lung cancer, including those with adenocarcinoma, say MONET1 investigators.

24 Jul 2012

Anti-IL-3 monoclonal antibodies to treat early stage Rheumatoid Arthritis in development

SuppreMol GmbH, an autoimmune disease specialist, today announced a licensing agreement with the University Hospital of Regensburg to develop SM401, a humanized anti-IL-3 monoclonal antibody for early diagnosis and treatment of Rheumatoid Arthritis (RA). SuppreMol will advance preclinical development of SM401 for treatment of RA. Simultaneously, the Company will further validate a highly sensitive human IL-3 diagnostic assay for patient stratification.

24 Jul 2012

Neural precursor cells suppress aggressive tumors

Neural precursor cells (NPC) in the young brain suppress certain brain tumors such as high-grade gliomas, especially glioblastoma (GBM), which are among the most common and most aggressive tumors.

23 Jul 2012

Experts examine host recognition of Staphylococcus and E.coli bacteria

We are surrounded by bacteria, viruses, fungi and parasites. The fact that we nevertheless do not fall prey to infections is thanks to certain cellular sensor molecules such as toll-like receptors (TLR), which recognize the molecular structure of pathogens and intercede by ensuring an often completely unnoticeable elimination of the invaders. Their immune-activating abilities were only detected in 1998, a discovery which was awarded with the Nobel Prize

21 Jul 2012

Receptor News and Research

Encouraging results from Tonix TNX-102 SL clinical trial for fibromyalgia syndrome

Study extends scientific understanding of how pheromones activate the vomeronasal organ

Fruit flies help pinpoint genetic changes that spell cancer

New drug can aid in losing weight and keeping it off

A2bAR receptor plays a significant role in regulation of type 2 diabetes and obesity

Navidea announces results from Lymphoseek Phase 3 trial on head and neck squamous cell carcinoma

Fusion of FGFR and TACC gene leads to glioblastoma

Insomnia: an interview with Dr Darryle Schoepp

Molecular explanation for increased susceptibility to intestinal inflammation in malnutrition

MASL protein from plant's seeds may halt spread of melanoma

Mice have different neural subsystem associated with instinctually important smells

Biokine receives FDA Orphan Drug designation for BKT140 to treat hematological cancers

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

Anti-IL-3 monoclonal antibodies to treat early stage Rheumatoid Arthritis in development

Neural precursor cells suppress aggressive tumors

Experts examine host recognition of Staphylococcus and E.coli bacteria

Novartis receives FDA approval for Afinitor to treat HER2-negative breast cancer

Unsuccessful fertility treatment reduces young-onset breast cancer risk

VDR polymorphisms may predict vitiligo in Chinese individuals

Iron deficiency in women ‘may be under-recognized’

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News